Objective. This study evaluates treatment of gastroparesis patients refractory to gastric electrical stimulation (GES) therapy with surgical replacement of the entire GES system. Summary Background Data. Some patients who have symptomatic improvement with GES later develop recurrent symptoms. Some patients improve by simply altering pulse parameter settings. Others continue to have symptoms with maximized pulse parameters. For these patients, we have shown that surgical implantation of a new device and leads at a different gastric location will improve symptoms of gastroparesis. Methods. This study evaluates 15 patients with recurrent symptoms after initial GES therapy who subsequently received a second GES system. Positive response to GES replacement therapy is evaluated by symptoms scores for vomiting, nausea, epigastric pain, early satiety, and bloating using a modified Likert score system, 0 to 4. Results. Total symptom scores improved for 12 of 15 patients with GES replacement surgery. Total score for the replacement group decreased from 17.3 ± 1.6 to 13.6 ± 3.7 with a difference of 3.6 (P value = .017). This score is compared with that of the control group with a preoperative symptom score of 15.8 ± 3.6 and postoperative score of 12.3 ± 3.5 with a difference of 3.5 (P value = .011). The control group showed a 20.3% decrease in mean total symptoms score, whereas the study group showed a 22.5% decrease in mean with an absolute reduction of 2.2. Conclusion. Reimplantation of a GES at a new gastric location should be considered a viable option for patients who have initially failed GES therapy for gastroparesis.
Introduction
Gastroparesis is a disabling condition characterized by decreased gastric motility, producing symptoms such as nausea, vomiting, early satiety, bloating, and epigastric pain. Gastroparesis is defined as delayed gastric emptying in the absence of mechanical obstruction. [1] [2] [3] [4] [5] [6] [7] [8] [9] In mild disease, treatment can be achieved with dietary management, including following a low-fiber and low-fat diet, making food particle sizes small, and having frequent and small meals. 10, 11 In moderate to severe disease, medical therapy is added. Common pharmaceuticals include prokinetic medications (metoclopramide, domperidone, erythromycin, and azithromycin), antiemetics (ondansetron and mirtazapine), tricyclic antidepressants, and the peptide hormone ghrelin. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Gastroparesis symptoms refractory to dietary and pharmaceutical modifications may respond to surgical therapy with gastric electrical stimulation (GES). GES is used to treat gastroparesis by delivering high-energy depolarizing stimuli to the stomach above the physiological slow-wave frequency of 3 cpm. This promotes gastric emptying and reduces symptoms of gastroparesis. GES therapy with the Enterra system has been shown to (1) reduce vomiting; (2) improve nausea and vomiting better than placebo; (3) reduce total symptom severity scores from severe to mild-moderate ranges; (4) increase quality of life; (5) increase weight; (6) decrease use of medications; (7) decrease the use of J-tubes; and (8) decrease medical billing costs compared with medical therapy alone. [22] [23] [24] [25] [26] [27] [28] [29] 32 Although it is uncommon, some patients who have symptomatic improvement with GES later develop recurrent symptoms. Sometimes, this can be corrected by altering device settings such as voltage, amplitude, and impedance to the external GES controller. Other complications with GES include lead displacement, dead battery, defective device, or infection around the device. These complications are easily corrected with an additional procedure to replace the dysfunctional component of the device. However, even without these complications, some patients still fail to respond to a functioning stimulator with correct placement of leads. This study evaluates treatment of GP patients refractory to GES therapy by replacing the entire GES system. We expect that the symptom scores of patients who undergo replacement GES therapy will significantly decrease.
Methods

Study Design
Data were retrospectively collected on all patients.
Patients
Study Group. A total of 15 patients with recurrent symptoms after initial GES therapy received a second implantation of a new GES system. Of these, 12 patients had a preoperative diagnosis of idiopathic gastroparesis, whereas 3 patients had diabetic gastroparesis. Of the 15 who underwent replacement GES surgeries, 11 were women and 4 were men, with an average age of 44 (range = 30-63) years. Recurrent symptoms developed on average 48 months (range = 9-130 months) after initial GES placement.
Control Group. For the control arm, 15 patients with positive response to GES therapy without developing recurrent symptoms were selected from a pool of 87 patients matched by the 3 variables of investigator-derived independent outcome score (IDIOMS), baseline symptom scores before initial GES implantation, and etiology of disease (ie, diabetic or idiopathic).
Criteria
Each patient met specific indications to receive GES replacement surgery. All patients had a preoperative diagnosis of drug-refractory diabetic, idiopathic, or postsurgical gastroparesis and disordered gastric emptying with or without significant weight change. Patients who initially had symptomatic improvement with GES and later developed recurrent symptoms were evaluated for GES replacement therapy. They were evaluated over a 1-to 2-week period with insertion of a temporary endoscopic gastric stimulator. Patients with a positive response to temporary stimulation received GES replacement surgery. Common gastroparesis symptoms were evaluated before and after GES replacement using the Likert score system (0 to 4). These symptoms include vomiting, nausea, epigastric pain, early satiety, and bloating. Additionally, preoperative gastric emptying times (GETs) and serosal electrogastrogram (EGG) recordings for frequency and amplitude at the time of GES placement were evaluated to reinforce physiological similarity between the 2 groups.
Procedure
Prior to the replacement GES procedure, patients undergo a trial, temporary GES to assess if the replacement procedure is warranted. During trial GES, a temporary cardiac pacing lead is placed endoscopically through the nose and inserted into the gastric mucosa in the middle of the stomach. After 1 to 2 weeks of temporary stimulation, patients are revaluated for symptom improvement. Patients with positive response receive GES replacement.
GES replacement surgery is similar to the initial GES implantation. The old pacemaker and leads are left in place to avoid contamination and damage to underlying muscle. A new pacemaker pocket is made for insertion of a new GES box. New gastric electrodes are inserted in a different location of the seromuscular layer on the anterior surface between the middle and medial third of the stomach. The stomach is examined endoscopically to make sure the new leads have not penetrated the lumen of the stomach. An EGG is used to record gastric myoelectric activity and for GES programming.
Analysis
Data were analyzed using a paired t test and reported as mean ± standard deviation.
Results
Symptoms scores of the gastroparesis patients who had recurrent symptoms after an initial good response and who subsequently received GES replacement (the study group) were compared with those of gastroparesis patients without recurrent symptoms with initial good response to GES (the control group). In Table 1 , we compare the total symptom scores before and after GES therapy for all 5 gastroparesis symptoms using the Likert scale (0-4) for a total scale of 0 to 20. Baseline scores for both groups were recorded prior to initial GES placement, whereas postoperative scores were recorded after the replacement surgery (or after initial GES placement for the control group). Of 15 patients, 12 with replacement GES showed improvement in total symptom scores post-GES replacement. In Table 2 , we compare preoperative and postoperative symptom scores for individual symptoms, the mean difference in preoperative and postoperative scores for each group, and the significant difference between the preoperative and postoperative scores. There were statistically significant improvements in vomiting, early satiety, and total symptoms scores for the replacement GES group. In Table 3 , we reinforce the physiological similarity between the 2 groups and compare mean serosal EGG values. EGG data include frequency; amplitude; frequency/amplitude ratio; GET at 1, 2, and 4 hours; and total GET. Figure 1 shows the change in mean total symptoms score of the study group compared with that of the control group. Patients without recurrent symptoms (control group) show a 20.3% decrease in mean total symptoms score, whereas patients with recurrent symptoms and GES replacement therapy (study group) show a 22.5% decrease in mean with an absolute reduction of 2.2. This is consistent with what is found in the literature. Musunuru et al 30 also found no significant differences in preoperative total symptom scores for GES responders and nonresponders.
Discussion
GES for gastroparesis is becoming the treatment of choice for gastroparesis refractory to dietary and medical treatment. 25, 26, 28, 29 Although GES therapy relieves symptoms in many patients, there is much uncertainty of how to predict response to therapy. Positive predictors of GES response are diabetic versus idiopathic gastroparesis, no analgesic use, normal interstitial cells of cajal (ICC), and absence of mental health factors. 30, 31 Recent studies suggest that decreased ICC can be predicted by tachygastric rhythm on EGG and may be of use in the future. In our study, 15 patients with GES had an initial positive response to GES and later developed recurrent symptoms. These patients received temporary endoscopic gastric electric stimulation for 1 week and showed symptomatic improvement. With positive response to temporary GES, a second surgery was planned for GES reimplantation. Of the 15 patients, 12 had improved gastroparesis symptoms after GES replacement.
Although there are many unknown factors to GES response, scarring of the gastric wall around the electrodes was correlated with decreased relief with GES therapy in our patients. We believe that temporary endoscopic gastric stimulation is of great value when predicting GES response. All 3 patients who did not respond to GES replacement had a preoperative diagnosis of idiopathic gastroparesis. One patient also suffered from fibromyalgia, which may mimic the symptoms of gastroparesis. The other 2 patients were evaluated for myenteric plexus inflammation with immunocytochemical studies, but the pathology was noncontributory. It is unknown why these patients failed GES replacement therapy. There are obvious limitations to this study, including the small sample size and the fact that this is a retrospective study. There is no clear explanation of why the original GES did not relieve symptoms. More research is necessary to determine positive and negative predictors of GES therapy.
Conclusion
A trial of temporary endoscopic gastric mucosal electrical stimulation followed by implantation of new leads and stimulator successfully salvages the majority of patients whose primary gastric electrical stimulator is no longer relieving symptoms. Reimplantation of a pacemaker at a new site in the stomach should be considered a viable option for patients who have initially failed GES therapy for gastroparesis.
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